Loading
NASDAQHealthcareBiotechnology
Latest quote
$143.73
+$3.82 · +2.73%
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Previous close
$143.73
+$3.82 · +2.73%
Regular session · ET · Market data may be delayed.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Day range
Current $143.73
52-week range
Current $143.73
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
59
Mixed
Risk
46
Elevated Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Day range
Current $143.73
52-week range
Current $143.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 46.02M USD | 434.43M USD | 60M USD | 26.58M USD | 27.36M USD |
| Cost of goods sold | 1.23M USD | — | — | — | — |
| Gross profit | 44.79M USD | 434.43M USD | 60M USD | 26.58M USD | 27.36M USD |
| Research and development | 159.29M USD | 138.13M USD | 120.16M USD | 126.22M USD | 126.01M USD |
| Selling, general, and administrative | 44.85M USD | 43.46M USD | 33.49M USD | 31.74M USD | 27.2M USD |
| Operating expenses | 202.92M USD | 181.59M USD | 153.65M USD | 157.95M USD | 153.2M USD |
| Interest income | 28.79M USD | 26.32M USD | 14.9M USD | 4.06M USD | 443K USD |
| Depreciation and amortization | 1.28M USD | 2.96M USD | 3.31M USD | 3.37M USD | 2.78M USD |
| Operating income | −158.13M USD | 252.84M USD | −93.65M USD | −131.37M USD | −125.85M USD |
| Net income | −130.15M USD | 275.19M USD | −78.96M USD | −127.39M USD | −125.55M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$176.29
22.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR540.63M0.52%103.19B USD0.06%$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI302.79M0.01%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM226.78M0.29%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB218.67M0.12%185.3B USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI143.7M1.46%9.87B USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK125.48M0.27%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF103.78M0.11%95.4B USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM83.19M0.53%15.84B USD0.03%$53.45+0.17%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
